Novartis AG (XSWX:NOVNEE) Operating Income: CHF13,596 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NOVNEE Novartis AG XSWX:NOVNEE
80 GF Score
Price CHF119.30
GF Value CHF98.69
! 7 Warning Signs
View Full Analysis

What is Novartis AG Operating Income?

Novartis AG XSWX:NOVNEE -0.52% 80 Operating Income is CHF13,596 Mil as of Jun. 2026. GuruFocus rates XSWX:NOVNEE with a GF Score™ of 80/100 and a GF Value™ of CHF98.69. The stock has 7 warning signs investors should review.

Novartis AG's Operating Income for the three months ended in Jun. 2026 was CHF3,797 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was CHF13,596 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Novartis AG's Operating Income for the three months ended in Jun. 2026 was CHF3,797 Mil. Novartis AG's Revenue for the three months ended in Jun. 2026 was CHF11,950 Mil. Therefore, Novartis AG's Operating Margin % for the quarter that ended in Jun. 2026 was 31.77%.

Good Sign:

Novartis AG operating margin is expanding. Margin expansion is usually a good sign.

Novartis AG's 5-Year average Growth Rate for Operating Margin % was 8.60% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Novartis AG's annualized ROC % for the quarter that ended in Jun. 2026 was 12.32%. Novartis AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 155.62%.


Novartis AG  (XSWX:NOVNEE) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Novartis AG's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=15186.7 * ( 1 - 23.71% )/( (92247.941 + 95804.098)/ 2 )
=11585.93343/94026.0195
=12.32 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=93320.244 - 4825.362 - ( 5492.992 - max(0, 24700.75 - 20947.691+5492.992))
=92247.941

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=97540.977 - 5251.401 - ( 6146.617 - max(0, 25376.176 - 21861.654+6146.617))
=95804.098

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Novartis AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=15125.952/( ( (9634.977 + max(-3205.886, 0)) + (9805.013 + max(-1952.689, 0)) )/ 2 )
=15125.952/( ( 9634.977 + 9805.013 )/ 2 )
=15125.952/9719.995
=155.62 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7389.598 + 4948.968 + 2946.076) - (4825.362 + 0 + 13665.166)
=-3205.886

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7702.055 + 4971.646 + 2867.089) - (5251.401 + 0 + 12242.078)
=-1952.689

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Novartis AG's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=3796.675/11950.334
=31.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Novartis AG Operating Income Related Terms


Novartis AG Operating Income Historical Data

* Premium members only.

The historical data trend for Novartis AG's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Operating Income Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,261.58 7,402.49 8,448.23 12,967.43 14,060.50

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,955.41 3,583.25 2,881.59 3,334.22 3,796.68
XSWX:NOVNEE
80GF Score
Novartis AG XSWX:NOVNEE
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF13,596 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of CHF13,596 Mil mean?
Novartis AG (XSWX:NOVNEE) has a Operating Income of CHF13,596 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Novartis AG and its competitors.
Is Novartis AG's Operating Income too high?
Novartis AG's current Operating Income is CHF13,596 Mil. Overall, Novartis AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Operating Income compare to LLY and JNJ?
Novartis AG's Operating Income of CHF13,596 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Novartis AG and its competitors. Novartis AG's current Operating Income is CHF13,596 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (XSWX:NOVNEE) has a current Operating Income of CHF13,596 Mil. The stock's GF Value™ is CHF98.69, compared to a current price of CHF119.30 — trading 20.9% above its estimated fair value. The current Operating Income is CHF13,596 Mil. Novartis AG's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Novartis AG (XSWX:NOVNEE), the current Operating Income is CHF13,596 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (XSWX:NOVNEE) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of CHF119.30 is trading 20.9% above its estimated GF Value™ of CHF98.69.

Key valuation signals for XSWX:NOVNEE:

  • Operating Income: CHF13,596 Mil
  • GF Value™: CHF98.69 vs. price of CHF119.30 (20.9% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NOVNEE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for XSWX:NOVNEE

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF119.30
Price
CHF98.69
GF Value